Thrombolysis of occluded peripheral arteries and veins with tenecteplase: A pilot study

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 11, 2002, Pages 1099-1102

  Burkart, David J ^a   Borsa, John J ^a   Anthony, James P ^a   Thurlo, Stephanie R ^a  

^a Saint Joseph Health Center   (United States)

Author keywords

Peripheral vascular disease; Tenecteplase; Thrombolysis

Indexed keywords

FIBRINOGEN; HEPARIN; TENECTEPLASE; TNK;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; VEIN OCCLUSION;

EID: 0036847873     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61950-2     Document Type: Article

References (12)

1. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 2000; 11:149-161.
2. Swischuk JL, Fox PF, Young K, et al. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: Results and complications. J Vasc Interv Radiol 2001; 12:423-430.
3. Arepally, Hofmann LV, Kim HS, et al. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol 2002; 13:45-50.
4. Davidian MM, Powell A, Benenati JF, Katzen BT, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11:289-294.
5. Castaneda F, Ruizong K, Young K, Swischuk JL, Smouse B, Brady T. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: Immediate results and complications from a pilot study. J Vasc Interv Radiol 2002; 13:577-580.
6. Refino CJ, Paoni NF, Keyt BA, et al. A variant of t-PA T103N, KHRR296-299 AAAA that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993; 70:313-319.
7. Keyt B, Paoni NF, Refino CJ, et al. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91:3670-3674.
8. Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72:98-104.
9. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human recombinant tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared to recombinant TPA. Circulation 1995; 92:3032-3040.
10. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet 1999; 354:716-722.
11. Patel N, Sacks D, Patel RI, et al. SCVIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol 2001; 12:559-570.
12. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg 1997; 26:517-538.